Harvoni Lawsuit

* We are not currently accepting cases for this lawsuit *

 

Harvoni is a prescription medication used alone or in combination with other drugs to treat chronic hepatitis C in all six genotypes of the infection. It is considered to be extremely effective and known as a cure for hepatitis C, but now there is evidence it might not be safe for patients who have had hepatitis B infections.

The US Food and Drug Administration (FDA) recently issued its strongest available warning concerning the risk associated with Harvoni. According to the information from the agency, it is possible for any patient using Harvoni and other direct-acting antivirals (DAAs) similar to Harvoni, and with a history of hepatitis B, to suffer a recurrence of that virus. Furthermore, there is evidence that reactivation in patients treated with Harvoni could result in serious and potentially fatal liver problems.

So far, the FDA has identified 24 cases of hepatitis B reactivation. The agency indicated this is just a small portion of those affected in this manner from using Harvoni.

In response to its concern, the FDA is now requiring all manufacturers of hepatitis C drugs to add a Boxed Warning about hepatitis B reactivation. The agency has also recommended that healthcare practitioners screen all hepatitis C patients for hepatitis B before prescribing Harvoni and other DAAs, and it has asked doctors to monitor patients currently receive hepatitis C treatment.

Why Wasn’t the Link Discovered before It Put Patients at Risk?

Testing was performed on Harvoni and other hepatitis C drugs, proving them to be effective for curing the virus. However, the test group patients did not include anyone who had previously been infected with hepatitis B. There was no way the manufacturers and researchers would have recognized a problem until those in this sub-group began using the medication – something that did not occur until after Harvoni had receive FDA approval.

According to statistics from the Centers for Disease Control and Prevention, there could be as many as 3.9 million people in the United States with hepatitis C infections. Hepatitis B infections could be present in as many as 2.2 million people.

Now, investigations are underway to determine whether legal action against Harvoni’s manufacturer and other makers of hepatitis C drugs is appropriate. Many legal experts believe those injured or harmed by a hepatitis B reactivation could be eligible for financial compensation.

If you or a loved one was prescribed Harvoni for treating hepatitis C and you suffered a reactivation of a previous hepatitis B infection and/or liver damage from your use of the drug, contact us for more information.

Additional Resource: https://www.drugdangers.com/harvoni/lawsuit/


 

* We are not currently accepting cases for this lawsuit *

FREE CASE EVALUATION

Since its establishment in 1999, Seeger Weiss has led some of the most complex and high-profile litigations in the U.S.